Literature DB >> 11415996

Enhanced epidermal growth factor receptor signaling in MCF7 breast cancer cells after long-term culture in the presence of the pure antiestrogen ICI 182,780 (Faslodex).

R A McClelland1, D Barrow, T A Madden, C M Dutkowski, J Pamment, J M Knowlden, J M Gee, R I Nicholson.   

Abstract

This paper describes the establishment of an antiestrogen-resistant MCF7 breast cancer cell subline (FASMCF) by continuous culture of the estrogen-responsive parental line in steroid-depleted, ICI 182,780 (Faslodex; 10(-7) M)-supplemented medium. After a 3-month period of growth suppression, cells began to proliferate in ICI 182,780 at rates similar to those of untreated wild-type cells. Immunocytochemistry showed these cells to have reduced estrogen receptor and an absence of progesterone receptor proteins. RT-PCR and transient transfection studies with estrogen response element-reporter constructs confirmed that ICI 182,780-suppressed estrogen response element-mediated signaling. FASMCF cells show increased dependence upon epidermal growth factor receptor (EgfR)/mitogen-activated protein kinase (MAPK)-mediated signaling. Thus, EgfR protein and messenger RNA, growth responses to transforming growth factor-alpha, and extracellular signal-regulated kinase 1/2 MAPK activation levels are all increased. Unlike wild-type cells, FASMCF cells are highly sensitive to growth inhibition by an EgfR-specific tyrosine-kinase inhibitor (TKI), ZD1839 (Iressa), and an inhibitor of the activation of MEK1 (MAPKK), PD098059. Short-term ( approximately 3 weeks) withdrawal of cells from antiestrogen had no effect on growth or phenotype, whereas longer withdrawal (>10 weeks) appeared to partially reverse the cellular phenotype with increasing estrogen receptor and decreasing EgfR levels. In subsequent studies FASMCF cells were maintained in TKI, where their growth was again suppressed and secondary TKI resistance failed to develop within the 3-month period in which initial ICI 182,780 resistance arose. Furthermore, wild-type cells similarly maintained in combination ICI 182,780 and TKI treatment conditions remained growth arrested (>6 months), with notable cell loss through both reduced rates of cellular proliferation and increased cell death.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11415996     DOI: 10.1210/endo.142.7.8259

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  60 in total

Review 1.  The role of the epidermal growth factor receptor in breast cancer.

Authors:  Samuel K Chan; Mark E Hill; William J Gullick
Journal:  J Mammary Gland Biol Neoplasia       Date:  2006-01       Impact factor: 2.673

Review 2.  The emerging role of the LIV-1 subfamily of zinc transporters in breast cancer.

Authors:  Kathryn M Taylor; Helen E Morgan; Kathryn Smart; Normawati M Zahari; Sara Pumford; Ian O Ellis; John F R Robertson; Robert I Nicholson
Journal:  Mol Med       Date:  2007 Jul-Aug       Impact factor: 6.354

Review 3.  Growth factor signalling in endocrine and anti-growth factor resistant breast cancer.

Authors:  R I Nicholson; I R Hutcheson; H E Jones; S E Hiscox; M Giles; K M Taylor; J M W Gee
Journal:  Rev Endocr Metab Disord       Date:  2007-09       Impact factor: 6.514

Review 4.  Biological determinants of endocrine resistance in breast cancer.

Authors:  Elizabeth A Musgrove; Robert L Sutherland
Journal:  Nat Rev Cancer       Date:  2009-09       Impact factor: 60.716

Review 5.  Optimizing the use of neoadjuvant endocrine therapy.

Authors:  Laila S Agrawal; Ingrid A Mayer
Journal:  Curr Oncol Rep       Date:  2015-07       Impact factor: 5.075

6.  P53-mediated induction of Cox-2 counteracts p53- or genotoxic stress-induced apoptosis.

Authors:  Jeong A Han; Jong-Il Kim; Pat P Ongusaha; Daniel H Hwang; Leslie R Ballou; Alka Mahale; Stuart A Aaronson; Sam W Lee
Journal:  EMBO J       Date:  2002-11-01       Impact factor: 11.598

7.  Mechanisms of resistance to structurally diverse antiestrogens differ under premenopausal and postmenopausal conditions: evidence from in vitro breast cancer cell models.

Authors:  Ping Fan; Wei Yue; Ji-Ping Wang; Sarah Aiyar; Yan Li; Tae-Hyun Kim; Richard J Santen
Journal:  Endocrinology       Date:  2009-01-29       Impact factor: 4.736

8.  MEK Inhibitor Selumetinib (AZD6244; ARRY-142886) Prevents Lung Metastasis in a Triple-Negative Breast Cancer Xenograft Model.

Authors:  Chandra Bartholomeusz; Xuemei Xie; Mary Kathryn Pitner; Kimie Kondo; Ali Dadbin; Jangsoon Lee; Hitomi Saso; Paul D Smith; Kevin N Dalby; Naoto T Ueno
Journal:  Mol Cancer Ther       Date:  2015-09-17       Impact factor: 6.261

Review 9.  Pathways to tamoxifen resistance.

Authors:  Rebecca B Riggins; Randy S Schrecengost; Michael S Guerrero; Amy H Bouton
Journal:  Cancer Lett       Date:  2007-05-01       Impact factor: 8.679

10.  Mathematical models of the transitions between endocrine therapy responsive and resistant states in breast cancer.

Authors:  Chun Chen; William T Baumann; Jianhua Xing; Lingling Xu; Robert Clarke; John J Tyson
Journal:  J R Soc Interface       Date:  2014-05-07       Impact factor: 4.118

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.